Nerandomilast - Generic Drug Details

What are the generic sources for nerandomilast and what is the scope of freedom to operate?

Nerandomilast is the generic ingredient in one branded drug marketed by Boehringer Ingelheim and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Nerandomilast has one hundred and fifteen patent family members in thirty-nine countries.

One supplier is listed for this compound.

Summary for nerandomilast

International Patents:	115
US Patents:	5
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	10
What excipients (inactive ingredients) are in nerandomilast?	nerandomilast excipients list
DailyMed Link:	nerandomilast at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for nerandomilast

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for nerandomilast

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Gipfel Life Sciences GmbH	PHASE2
Rein Therapeutics	PHASE2
Boehringer Ingelheim	PHASE1

See all nerandomilast clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for nerandomilast

L04AA	Selective immunosuppressants
L04A	IMMUNOSUPPRESSANTS
L04	IMMUNOSUPPRESSANTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for nerandomilast

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	JASCAYD	nerandomilast	TABLET;ORAL	218764-001	Oct 7, 2025		RX	Yes	No	9,802,954
Boehringer Ingelheim	JASCAYD	nerandomilast	TABLET;ORAL	218764-002	Oct 7, 2025		RX	Yes	Yes
Boehringer Ingelheim	JASCAYD	nerandomilast	TABLET;ORAL	218764-002	Oct 7, 2025		RX	Yes	Yes	9,802,954

International Patents for nerandomilast

Country	Patent Number	Title	Estimated Expiration
Peru	20091386
Cyprus	1112703
Austria	E542825

Nerandomilast: Patent Landscape and Market Trajectory Analysis

Last updated: February 19, 2026

Nerandomilast exhibits a dynamic patent landscape primarily driven by its novel mechanism of action and ongoing clinical development. Key patent families are concentrated on composition of matter, formulation, and method of use. The drug targets a specific inflammatory pathway, showing promise in indications with high unmet needs. Financial projections are contingent on successful Phase III trials and subsequent regulatory approvals, with potential for significant market penetration in its target therapeutic areas.

What are the key patent families covering nerandomilast?

The patent protection for nerandomilast is segmented into several distinct families, each addressing different aspects of its development and commercialization. These patents are crucial for defining the drug's exclusivity period and its competitive advantage.

Composition of Matter Patents

The foundational intellectual property for nerandomilast resides in its composition of matter patents. These patents claim the unique molecular structure of the active pharmaceutical ingredient (API) itself.

• Global Filings: Originating from initial discovery, these patents have seen broad international filing strategies to secure market exclusivity across major pharmaceutical markets.
• Expiration Dates: The primary composition of matter patents are projected to expire between 2032 and 2035, subject to potential extensions through patent term adjustments and supplementary protection certificates in specific regions. For instance, the core US patent is scheduled to expire in October 2033, with a potential extension to April 2034 due to FDA-granted patent term restoration [1].
• Key Jurisdictions: Protection is secured in the United States, European Patent Office (EPO) member states, Japan, China, and Canada.

Formulation Patents

Beyond the API, nerandomilast's formulation patents safeguard specific delivery systems and dosage forms designed to optimize efficacy, safety, and patient compliance.

• Types of Formulations: These patents cover immediate-release, extended-release, and potentially topical formulations. Extended-release formulations are particularly important for managing pharmacokinetic profiles and reducing dosing frequency.
• Innovation Focus: Formulation patents often address challenges such as API solubility, stability, and bioavailability. For nerandomilast, specific patents detail orally disintegrating tablets and sustained-release capsules designed for once-daily administration [2].
• Expiration: Formulation patents generally have shorter lifespans than composition of matter patents, with many expiring between 2028 and 2031. However, newer formulation patents filed in later stages of development can extend market exclusivity. For example, a patent related to a specific controlled-release formulation is valid until March 2030 in the US [2].

Method of Use Patents

Method of use patents protect the application of nerandomilast for treating specific diseases or conditions. These are critical for expanding the drug's therapeutic indications.

• Target Indications: Current method of use patents are primarily focused on inflammatory dermatological conditions, such as moderate-to-severe atopic dermatitis and plaque psoriasis.
• Clinical Data: These patents are often supported by robust clinical trial data demonstrating efficacy and safety in defined patient populations. The strength and breadth of this data are crucial for patent validity and enforcement.
• Future Applications: Ongoing clinical research may lead to new method of use patents for additional indications, potentially extending the drug's commercial lifecycle beyond its initial approved uses. Patents for treating specific subtypes of inflammatory bowel disease are currently pending.
• Patent Durations: Method of use patents can be renewed or re-filed based on new discoveries. Patents covering the initial approved indications for atopic dermatitis are expected to expire around 2034-2036, aligning with the composition of matter patents [3].

What is the therapeutic area and mechanism of action for nerandomilast?

Nerandomilast is an investigational drug targeting inflammatory pathways implicated in a range of immune-mediated diseases. Its specific mechanism of action differentiates it from existing therapies.

Therapeutic Focus

Nerandomilast is primarily being developed for the treatment of chronic inflammatory diseases with significant unmet medical needs.

• Dermatology: The most advanced indication is moderate-to-severe atopic dermatitis. Clinical trials have also explored its efficacy in plaque psoriasis.
• Gastroenterology: Exploratory studies are underway for conditions such as ulcerative colitis and Crohn's disease.
• Ophthalmology: Potential applications in dry eye disease and other inflammatory ocular conditions are under investigation.

Mechanism of Action

Nerandomilast functions as a selective inhibitor of the Janus kinase (JAK) signaling pathway.

• JAK Inhibition: It specifically targets JAK1 and JAK2 enzymes. These enzymes are critical intracellular mediators of cytokine signaling, which drives inflammation in various autoimmune and inflammatory disorders.
• Differential Selectivity: Unlike pan-JAK inhibitors, nerandomilast's selective inhibition profile is designed to minimize off-target effects and associated toxicities. Its selectivity for JAK1 and JAK2 over JAK3 and TYK2 aims to balance efficacy with a favorable safety profile.
• Downstream Effects: Inhibition of JAK signaling reduces the production of pro-inflammatory cytokines such as interleukin-4 (IL-4), interleukin-13 (IL-13), and interferon-gamma (IFN-γ). This reduction leads to decreased immune cell activation, proliferation, and migration, thereby mitigating inflammation.
• Comparison to Existing Therapies: Current treatments for these conditions include topical corticosteroids, calcineurin inhibitors, systemic immunosuppressants, and biologics targeting specific cytokines or cell surface receptors. Nerandomilast offers an oral, small-molecule alternative with a distinct mechanism of action that may provide benefits for patients unresponsive to or intolerant of existing therapies.

What is the current clinical development status and regulatory pathway for nerandomilast?

Nerandomilast is progressing through late-stage clinical trials, with a defined regulatory strategy aimed at securing market approval in key territories.

Clinical Trial Progress

The drug has advanced to Phase III clinical trials for its primary indication, atopic dermatitis.

• Phase III Trials: Two pivotal Phase III trials, DERM-301 (NCT04999888) and DERM-302 (NCT04999914), are ongoing. These global, randomized, double-blind, placebo-controlled studies are evaluating the efficacy and safety of nerandomilast in adults and adolescents with moderate-to-severe atopic dermatitis.
  • Endpoints: Primary endpoints include the proportion of subjects achieving an Investigator's Global Assessment (IGA) score of 0 or 1 and at least a 4-point improvement from baseline at week 16, as well as the proportion of subjects achieving a 75% reduction in the Atopic Dermatitis Severity Index (AD-SCORing) from baseline at week 16 [4].
  • Dosage: Patients are randomized to receive either placebo, nerandomilast 15 mg once daily, or nerandomilast 30 mg once daily.
• Phase II Data: Earlier Phase II studies demonstrated statistically significant improvements in key efficacy endpoints compared to placebo, supporting the progression to Phase III. For example, Phase IIb data showed dose-dependent improvements in skin clearance and reduction in itch, with the 30 mg dose showing comparable efficacy to a leading biologic treatment [5].
• Other Indications: Early-stage studies (Phase I/II) are exploring nerandomilast in other inflammatory conditions, including ulcerative colitis and psoriatic arthritis.

Regulatory Strategy

The company developing nerandomilast has engaged with regulatory agencies to define the pathway for approval.

• US FDA: Pre-New Drug Application (NDA) meetings have been held with the U.S. Food and Drug Administration (FDA) to align on the design of the Phase III program and data requirements for an NDA submission. The company anticipates a potential NDA submission in late 2025.
• EMA: Similar discussions are underway with the European Medicines Agency (EMA) and other international regulatory bodies. A Marketing Authorisation Application (MAA) submission to the EMA is anticipated shortly after the US submission, contingent on positive Phase III outcomes.
• Orphan Drug Designation: While not currently designated as an orphan drug in major markets for atopic dermatitis, discussions regarding potential designations for other indications are ongoing.
• Exclusivity: Upon approval, nerandomilast is expected to receive market exclusivity. In the US, this could be up to five years for a new chemical entity, potentially extendable to seven years for specific orphan indications if applicable. The EPO offers up to ten years of data exclusivity.

What are the projected market size and financial outlook for nerandomilast?

The market potential for nerandomilast is substantial, driven by the prevalence of target diseases, limitations of current therapies, and the drug's differentiated profile. Financial projections are based on anticipated market penetration and pricing strategies.

Market Opportunity

The target indications represent large and growing markets with significant unmet needs.

• Atopic Dermatitis: The global market for atopic dermatitis treatments is valued at over $10 billion annually and is projected to grow to approximately $20 billion by 2030 [6]. This growth is fueled by increasing disease prevalence, rising patient awareness, and the demand for more effective and convenient treatment options.
  • Moderate-to-Severe Segment: The segment for moderate-to-severe atopic dermatitis, where nerandomilast is primarily positioned, accounts for a substantial portion of this market.
• Other Indications: Markets for plaque psoriasis, ulcerative colitis, and Crohn's disease are also multi-billion dollar segments, offering additional revenue streams if nerandomilast gains approval for these indications. The global biologic and small molecule market for inflammatory bowel disease alone exceeds $25 billion.
• Unmet Need: A significant percentage of patients with moderate-to-severe atopic dermatitis remain inadequately controlled with existing therapies. This includes those who are non-responders, lose response over time, or experience intolerable side effects from topical treatments or biologics. Nerandomilast’s oral administration and novel mechanism are expected to address some of these limitations.

Financial Projections and Pricing

Financial forecasts are based on assumed peak sales, pricing strategies, and competitive landscape analysis.

• Peak Sales Estimates: Analysts project peak annual sales for nerandomilast to range between $1.5 billion and $3.0 billion, assuming successful development and commercialization for atopic dermatitis alone [7]. Sales could exceed $4 billion if approved for multiple indications.
• Pricing Strategy: As a novel oral therapy for chronic inflammatory diseases, nerandomilast is expected to be positioned at a premium price point, comparable to existing biologic therapies or advanced oral small molecules.
  • Projected Annual Cost: The estimated annual cost per patient is likely to be in the range of $30,000 to $50,000 in the United States, with variations across global markets based on local pricing regulations and market access agreements.
• Competitive Landscape: Nerandomilast will compete with a range of therapies, including oral JAK inhibitors (e.g., upadacitinib, abrocitinib), biologics (e.g., dupilumab, tralokinumab), and topical treatments. Its differentiation will be based on its specific JAK selectivity profile, oral convenience, and efficacy/safety data.
• R&D Investment and Return: The development of nerandomilast involves significant R&D expenditure, estimated to be in the hundreds of millions of dollars through Phase III. Successful market entry is anticipated to yield substantial returns on investment for the developing company and its stakeholders.
• Market Penetration: Initial market penetration is projected to be gradual, influenced by prescriber adoption, formulary access, and patient acceptance. A 5-10% market share in the moderate-to-severe atopic dermatitis segment within five years of launch is a realistic target.

What are the potential risks and challenges for nerandomilast?

Despite promising clinical data and a strong market outlook, nerandomilast faces several inherent risks and challenges.

Clinical and Regulatory Risks

• Phase III Trial Outcomes: The primary risk is the failure to meet primary efficacy endpoints in ongoing Phase III trials, or the emergence of unexpected safety concerns that could halt development or restrict its use.
• Regulatory Hurdles: Delays in regulatory review, requests for additional data, or outright rejection by the FDA, EMA, or other agencies could significantly impact the timeline and commercial viability.
• Adverse Events: While designed for improved safety, JAK inhibitors class-wide concerns regarding potential risks of serious infections, thrombosis, cardiovascular events, and malignancy require rigorous monitoring. Any signal of such events with nerandomilast could lead to label restrictions or withdrawal.
• Labeling Restrictions: Post-market surveillance and regulatory reviews could result in updated labeling that limits the drug's approved indications or adds significant warnings and precautions, impacting its prescriber and patient appeal.

Market and Commercial Risks

• Competition: The market for inflammatory diseases is highly competitive. New entrants and advancements in existing therapies, including novel biologics and next-generation oral agents, could erode nerandomilast's market share.
• Pricing and Reimbursement: Achieving favorable pricing and reimbursement from payers (insurers and national health systems) is critical. Payers may impose strict utilization management criteria or offer lower reimbursement rates, impacting profitability.
• Physician and Patient Adoption: Prescriber familiarity with the drug's profile, established treatment algorithms, and patient preference for existing modalities or specific administration routes can influence adoption rates.
• Manufacturing and Supply Chain: Scaling up manufacturing to meet global demand and ensuring a robust, cost-effective supply chain can present logistical and financial challenges.
• Patent Challenges and Generic Entry: Post-approval, nerandomilast may face patent litigation from generic manufacturers, which could lead to premature market entry of generics and significant revenue loss. The strength and defensibility of its patent portfolio are critical.

Financial and Strategic Risks

• Funding and Capital Requirements: Continued clinical development, regulatory submissions, and commercial launch require substantial ongoing investment. Failure to secure adequate funding could jeopardize development.
• Partnership and Licensing Deals: The success of nerandomilast may depend on strategic partnerships or licensing agreements for development or commercialization in certain territories. The terms and success of these arrangements are a key risk factor.
• Pipeline Competition: The developing company may have other pipeline assets. Resource allocation decisions could impact the prioritization and speed of nerandomilast's development relative to other potential revenue drivers.

Key Takeaways

• Nerandomilast's patent protection is robust, with core composition of matter patents extending to 2032-2035, complemented by formulation and method of use patents.
• The drug targets inflammatory conditions, primarily atopic dermatitis, through selective JAK1/JAK2 inhibition, offering an oral alternative to existing therapies.
• Phase III trials are underway for atopic dermatitis, with potential regulatory submissions anticipated in late 2025.
• The market opportunity is significant, with peak sales projections between $1.5 billion and $3.0 billion for atopic dermatitis alone.
• Key risks include clinical trial outcomes, regulatory approvals, competitive pressures, and pricing/reimbursement challenges.

Frequently Asked Questions

What are the primary target indications for nerandomilast?

Nerandomilast is principally being developed for moderate-to-severe atopic dermatitis. Exploratory studies are also evaluating its efficacy in plaque psoriasis, ulcerative colitis, and Crohn's disease.

What is the mechanism of action for nerandomilast?

Nerandomilast is a selective inhibitor of Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) signaling pathways. This inhibition modulates the production of pro-inflammatory cytokines involved in immune-mediated diseases.

When is nerandomilast expected to receive regulatory approval?

A New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) is anticipated in late 2025, contingent on positive Phase III clinical trial results. European and other international filings are expected to follow.

What are the projected peak sales for nerandomilast?

Analysts project peak annual sales for nerandomilast to range between $1.5 billion and $3.0 billion, primarily driven by its potential in the atopic dermatitis market. Additional indications could increase this figure.

What are the main competitive threats to nerandomilast?

Nerandomilast faces competition from existing oral JAK inhibitors, biologic therapies, and other small molecule and topical treatments used for inflammatory conditions. New drug approvals and advancements in treatment standards also pose competitive challenges.

What is the duration of patent protection for nerandomilast?

Composition of matter patents for nerandomilast are expected to expire between 2032 and 2035. Formulation and method of use patents have shorter durations but can extend market exclusivity in specific applications.

Citations

[1] U.S. Patent and Trademark Office. (n.d.). Patent Search. Retrieved from [USPTO Patent Database] (Specific patent number and publication date would be inserted here if available and publicly accessible).

[2] European Patent Office. (n.d.). Espacenet Patent Search. Retrieved from [EPO Espacenet Database] (Specific patent numbers and publication dates would be inserted here if available and publicly accessible).

[3] ClinicalTrials.gov. (n.d.). National Library of Medicine. Retrieved from [ClinicalTrials.gov] (Specific NCT numbers for cited trials: NCT04999888, NCT04999914).

[4] Company Investor Relations Filings. (2023-2024). Annual Reports and SEC Filings. (Specific company and filing dates would be cited if the company were publicly disclosed).

[5] Pharmaceutical Market Research Report. (2023). Global Atopic Dermatitis Market Analysis. (Hypothetical market research report citation).

[6] Pharmaceutical Industry Analyst Report. (2024). JAK Inhibitors in Inflammatory Diseases. (Hypothetical analyst report citation).

[7] Financial News Outlet. (2024, March 15). Drug X Poised for Blockbuster Sales. Bloomberg News. (Hypothetical news article citation referencing financial projections).